A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA 50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naive, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast.

Trial Profile

A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA 50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naive, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Fozivudine (Primary) ; Efavirenz; Lamivudine; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2014 According to Pan-African Clinical Trials Registry, Status changed from not yet recruiting to active, no longer recruiting.
    • 11 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top